| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/30/2007 | EP1789419A1 Gyrase inhibitors and uses thereof |
| 05/30/2007 | EP1789417A1 AMIDE DERIVATIVES OF 7-AMINO-3-PHENYL-DIHYDROPYRIMIDO [4,5-d]PYRIMIDINONES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS |
| 05/30/2007 | EP1789416A2 Amide derivatives of 3-phenyl dihydropyrimido[4,5-d]pyrimidinones, their manufacture and use as pharmaceutical agents |
| 05/30/2007 | EP1789414A1 2-morpholino-4-pyrimidone compound |
| 05/30/2007 | EP1789413A1 Vanilloid receptor ligands and their use in treatments |
| 05/30/2007 | EP1789410A1 Methylene dipiperidine derivatives |
| 05/30/2007 | EP1789409A2 Sulfonamides and uses thereof |
| 05/30/2007 | EP1789408A1 Androgen modulators |
| 05/30/2007 | EP1789407A2 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| 05/30/2007 | EP1789406A1 Thioxothiazolidinone compounds for use as pharmaceuticals |
| 05/30/2007 | EP1789405A1 Novel enantiomerically pure beta-agonists, method for the production and the use thereof in the form of a drug |
| 05/30/2007 | EP1789404A2 Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors |
| 05/30/2007 | EP1789403A1 N-(phenyl-oxazol-4-ylmethoxymethyl)-cyclohexyl.succinic acid amide derivatives and related compounds which are used as ppar-ligands (peroxisome proliferator activated receptors) for the treatment of hyperlipidaemie and diabetes |
| 05/30/2007 | EP1789402A1 2-{-3-2-(phenyl)-oxazol-4-ylmethoxymethyl!-cyclohexylmethoxy };-propionic acid derivatives used as ppar ligandes (peroxisome proliferator-activated receptors) for the treatment of hyperlipidaemie and diabetes |
| 05/30/2007 | EP1789400A1 Quinazolinone derivatives and their use as b-raf inhibitors |
| 05/30/2007 | EP1789399A1 Quinazolinone derivatives and their use as b-raf inhibitors |
| 05/30/2007 | EP1789398A1 2-amino-quinazoline derivatives useful as inhibitors of b-secretase (bace) |
| 05/30/2007 | EP1789397A2 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide kcnq potassium channel modulators |
| 05/30/2007 | EP1789396A1 Substituted phenylacetamides and their use as glucokinase activators |
| 05/30/2007 | EP1789394A1 Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases |
| 05/30/2007 | EP1789390A2 Pyridyl inhibitors of hedgehog signalling |
| 05/30/2007 | EP1789389A1 Piperidine compound and process for preparing the same |
| 05/30/2007 | EP1789386A1 Substituted indole compounds, their preparation and use in medicaments |
| 05/30/2007 | EP1789381A2 Inhibitors of histone deacetylase |
| 05/30/2007 | EP1789380A1 Amino adamantane derivatives, methods for the production and use thereof |
| 05/30/2007 | EP1789139A1 Fumarate of 4-((4-((4-(2-cyanoethenyl)-2,6-dimethylphenyl|amino|-2-pyrimidinyl|amino|benzonitrile |
| 05/30/2007 | EP1789107A2 Medical stent provided with inhibitors of atp synthesis |
| 05/30/2007 | EP1789079A1 Enzyme inhibitors and uses thereof |
| 05/30/2007 | EP1789077A2 Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning |
| 05/30/2007 | EP1789068A2 Composition and method for prevention or treatment of stomatits |
| 05/30/2007 | EP1789059A2 Glycosylceramide adjuvant for saccharide antigens |
| 05/30/2007 | EP1789058A2 Rna interference vectors |
| 05/30/2007 | EP1789057A2 Neuroprotective effect of solubilized udca in focal ischemic model |
| 05/30/2007 | EP1789056A1 Use of steroid-derived pharmaceutical compositions for treating disorders relating to pathological processes in lipid rafts |
| 05/30/2007 | EP1789055A2 Thiazolopyridine kinase inhibitors |
| 05/30/2007 | EP1789054A2 Cannabinoid compositions and methods of use thereof |
| 05/30/2007 | EP1789053A2 Method of wound healing using a2b adenosine receptor antagonists |
| 05/30/2007 | EP1789052A1 Composition and method for inducing or restoring locomotor functions in an animal |
| 05/30/2007 | EP1789051A1 Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof |
| 05/30/2007 | EP1789050A1 Novel quinoxalinone norepinephrine reuptake inhibitors for the treatment of central nervous system disorders |
| 05/30/2007 | EP1789049A2 Cyclic amide and ester pyrazinoylguanidine sodium channel blockers |
| 05/30/2007 | EP1789048A1 Method for the treatment of attention deficit hyperactivity disorder |
| 05/30/2007 | EP1789047A2 Treatment of diseases using nalmefene and its analgos |
| 05/30/2007 | EP1789046A2 Peripheral benzodiazepine receptor independent superoxide generation |
| 05/30/2007 | EP1789045A2 Chemical compounds |
| 05/30/2007 | EP1789044A1 Phenylaminopyridines |
| 05/30/2007 | EP1789043A2 Compositions and methods for treating or preventing hepadnaviridae infection |
| 05/30/2007 | EP1789042A2 1-alkoxy 1h-imidazo ring systems and methods |
| 05/30/2007 | EP1789041A2 Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors |
| 05/30/2007 | EP1789040A2 Halogenated benzamide derivatives |
| 05/30/2007 | EP1789039A2 S-triazolyl alpha -mercaptoacetanildes as inhibitors of hiv reverse transcriptase |
| 05/30/2007 | EP1789038A1 Combination of substituted benzimidazoles and triazine derivatives with antiparasitic action |
| 05/30/2007 | EP1789037A1 Gastric therapies and compositions therefor |
| 05/30/2007 | EP1789036A2 5-ý3-(4-benzyloxyphenylthio)-fur-2-yl¨-imidazolidin-2, 4-dione and analogues as inhibitors of macrophage elastase |
| 05/30/2007 | EP1789035A2 Orally administered small peptides synergize statin activity |
| 05/30/2007 | EP1789034A1 Compounds with diphenoyl -structure for the treatment of immune diseases |
| 05/30/2007 | EP1789033A2 Glycine as a diet supplement for the treatment of health problems that result from underlying metabolic disorders |
| 05/30/2007 | EP1789032A2 Use of thyroid hormone conversion inhibitors |
| 05/30/2007 | EP1789031A2 Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists |
| 05/30/2007 | EP1789030A2 Medical implant provided with inhibitors of atp synthesis |
| 05/30/2007 | EP1789029A2 Methods and compositions for the treatment of cell proliferation |
| 05/30/2007 | EP1789028A2 Compositions for treating nociceptive pain |
| 05/30/2007 | EP1789027A2 Therapeutic use of anti-tf-antigen antibody |
| 05/30/2007 | EP1789021A2 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
| 05/30/2007 | EP1789020A2 Pharmaceutical dosage forms comprising a low-solubility drug and a polymer |
| 05/30/2007 | EP1789019A2 Powders containing novel oligosaccharide mixtures and methods for producing the same |
| 05/30/2007 | EP1789018A1 Enhanced delivery of drug compositions to treat life threatening infections |
| 05/30/2007 | EP1788980A2 Multi-functional biocompatible coatings for intravascular devices |
| 05/30/2007 | EP1788876A1 Method for manufacturing imidazole compounds and salts and pseudopolymorphs thereof |
| 05/30/2007 | EP1788874A2 Salts of 5-azacytidine |
| 05/30/2007 | EP1709014B1 Antidiabetic oxazolidinediones and thiazolidinediones |
| 05/30/2007 | EP1675891B1 Pectin films prepared from gamma irradiated pectin |
| 05/30/2007 | EP1673372B1 Non-amide nonanes |
| 05/30/2007 | EP1648895B1 Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction |
| 05/30/2007 | EP1562940B1 Aryl sulfonamides |
| 05/30/2007 | EP1556372B1 Substituted 4-amino-1-(pyridylmethyl) piperidine as muscarinic receptor antagonists |
| 05/30/2007 | EP1539743B1 Pyrazole derivatives as gnrh inhibitors |
| 05/30/2007 | EP1536785B1 Novel ppar ligands that do not cause fluid retention, edema or congestive heart failure |
| 05/30/2007 | EP1531797A4 Biodegradable block copolymeric compositions for drug delivery |
| 05/30/2007 | EP1509212B1 Novel chromium (iii) alpha amino acid complexes |
| 05/30/2007 | EP1499577B1 2-(2,6-dichlorophenyl)-diarylimidazoles |
| 05/30/2007 | EP1496925A4 Use of interleukin-24 to treat ovarian cancer |
| 05/30/2007 | EP1492560A4 Use of interleukin-19 to treat cervical cancer |
| 05/30/2007 | EP1490052B1 Device for the transdermal administration of a rotigotine base |
| 05/30/2007 | EP1487818B1 Alkylammonium salts of omeprazole and esomeprazole |
| 05/30/2007 | EP1458672B1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha(ppar) |
| 05/30/2007 | EP1450767B1 Microspherules containing a pleuromutilin derivative |
| 05/30/2007 | EP1429763B1 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER |
| 05/30/2007 | EP1427706B1 Substituted pyrazolo compounds for the treatment of inflammation |
| 05/30/2007 | EP1417211B1 Natural phospholipids of marine origin containing flavonoids and polyunsaturated phospholipids and their uses |
| 05/30/2007 | EP1406568B1 Sequential drug delivery systems |
| 05/30/2007 | EP1392291B1 Tripeptidyl peptidase inhibitors |
| 05/30/2007 | EP1389109B1 Gastric acid secretion inhibiting composition |
| 05/30/2007 | EP1385527B1 Use of 2-alpha-cyano-4-alpha, 5-alpha-epoxyandrostan-17-beta-ol-3-one derivatives for lowering levels of serum cortisol and for the treatment of clinical conditions associated thereof |
| 05/30/2007 | EP1373487B1 Regulation of human protein kinase-like protein |
| 05/30/2007 | EP1373220B1 Benzimidazoles that are useful in treating sexual dysfunction |
| 05/30/2007 | EP1318814B1 Triazole compounds useful as protein kinase inhibitors |
| 05/30/2007 | EP1299108A4 A parasiticidal formulation and a method of making this formulation |
| 05/30/2007 | EP1294356B1 Sustained release delivery systems for solutes |
| 05/30/2007 | EP1285655B1 Stabilized pharmaceutical compositions containing the calcium channel blocker azelnidipine |